Federico Massa

Neurologist, PhD in Clinical and Experimental Neuroscience and research fellow at DINOGMI, University of Genoa, Italy, and Policlinico San Martino IRCCS.

[Lilly Neuroscience International @LillyNeuroInt]

The early and accurate detection of #AlzheimersDisease enables
patients and their care partners to plan for the future and make
appropriate lifestyle changes that could help maintain their quality of life for longer.³ Watch Dr. Massa’s opinion on this topic here:

[Brain @Brain1878]

Barba et al. review the co-occurrence of Alzheimer's disease and Lewy body disease pathologies, and consider the diagnostic and prognostic value of neuroimaging and fluid biomarkers. https://t.co/M4GgccTbt2

[Lorenzo Barba @lorbarba]

Extraordinarily excited for our work to be published in @Brain1878 today!

We extensively discuss the clinical and diagnostic implications of #Alzheimer’s disease copathology in Lewy body disease 🧠

@s_rumeileh
@fedemassa88
@mattfos89
@unimedizinhalle

https://t.co/gnU1BNbLwb

[AD/PD - Advances in Science & Therapy @adpdnet]

Thank you for an amazing 5 days filled with science, inspiring talks, insights, and networking! 🤩

We hope to welcome you again at the next edition of AD/PD™ on April 1-5, 2025 in Vienna, Austria. 📅

Stay tuned for more information!

#ADPD2025

[Lilly Neuroscience International @LillyNeuroInt]

Watch our latest video from this year’s #ADPD24 in Lisbon. Dr. Federico Massa shares his thoughts on identifying genetic causes underlying #AlzheimersDisease.¹ For Healthcare professionals.

[Lorenzo Barba @lorbarba]

Honored to share this excellent meta-analysis out on JNNP! All levels (even low levels) of leisure-time physical activity are beneficial for stroke prevention 🏃🏻‍♂️🧠
@RaffaeleOrnello
@s_rumeileh
@mattfos89
@fededs00
@MicheleRomoli
@luciodanna2
@Simona_Sacco_
https://t.co/9Ynm0UhGhT

[Federico Massa @fedemassa88]

If interested in molecular imaging biomarkers for early diagnosis and prognosis of early-stage dementias, see our updated systematic review of recent literature. #MCI #dementia #PET #Alzheimer #nuclearmedicine
See EJNMMI:https://t.co/ER9G39AAxn https://t.co/zVCbuEzhhZ

[Federico Massa @fedemassa88]

Could not be prouder for contributing to this oustanding project: European expert-shared recommendations for a cost-effettive use of biomarkers in early dementia are now on @TheLancetNeuro
Have a glance: https://t.co/mpcXfi903M

@GiovanniFrisoni
@SanMartino_Ge @UniGenova

[Federico Massa @fedemassa88]

Happy to share our work published with @SpringerNature on J of Neurology. If interested on the changes of cerebrospinal fluid levels of NPTX2 and association with brain metabolism metrics in MCI-AD, just read and share: https://t.co/txP9p3lmep
🇮🇹🇩🇪🧠
@UniGenova @SanMartino_Ge

[Lorenzo Barba @lorbarba]

Honored to share my first #Neurology paper!
In this work, we show that CSF synaptic biomarkers (SNAP25, ng, α-syn, β-syn) are similarly increased in patients with AD and mixed LBD-AD compared to controls and pure LBD cases 💉🧠😃
@s_rumeileh @GreenJournal
https://t.co/wPJwPmcW1P

[Pietro Mattioli @PietMattioli]

Dear all,
happy to share our recently published article on Pisa syndrome!!!
Right posterior hypometabolism in Pisa syndrome of Parkinson’s disease: A key to explain body schema perception deficit? https://t.co/j2K870QCsR
@ParkinsonismD

[Francesco Lanfranchi @flanfranchiMD]

It's out! Our work about DaT SPECT in #Parkinson disease and #dementia with Lewy bodies has been published by #EJNMMI! Congratulations and many thanks to all the authors @DarioArnaldi, @PietMattioli, @fedemassa88, @MatteoBauckneht and @SilviaMorbelli!
https://t.co/EfIK1n5I7N

[European Association of Nuclear Medicine (EANM) @EANM_NucMed]

We are glad to announce the first article of the 'European Consensus for the diagnosis of MCI and mild dementia', in which the #EANM participated! Stay tuned for further articles on this initiative.

Many thanks to the EANM Neuroimaging Committee!
https://t.co/sMlNfae6EU

[Federico Massa @fedemassa88]

Glad to be part of this ambitious project! The paper on the methodology and preliminary results of the European consensus for the efficient use of biomarkers in the etiological diagnosis of MCI and mild dementia is now available: https://t.co/RTpPFrRUlf #dementiaresearch

[Lorenzo Barba @lorbarba]

Excited to share our last paper published in @JNNP_BMJ, in which we highlight the remarkable increase of CSF beta-synuclein in the preclinical phase of #Alzheimer disease 🧠🇮🇹🇩🇪

@s_rumeileh @fedemassa88 @unimedhal @UniperugiaNews
https://t.co/5BU6xEm733

[JAMA Neurology @JAMANeuro]

Study found that early-onset #dementia with Lewy bodies (DLB) was often misdiagnosed as Alzheimer disease, while #Alzheimerdisease co-pathology was more common in later-onset DLB. https://t.co/8opfHxTDh7

[Nat Rev Neurology @NatRevNeurol]

A history of hypothyroidism is associated with an increased risk of dementia in people aged ≥65 years https://t.co/mFsInG8CXv

[Sant Pau Memory Unit @SantPauMemory]

👀Markers of #Alzheimer in #plasma measured in an automated platform showed a great accuracy

The details have been presented by Dr. Alcolea in the 3rd #CSFSociety meeting held in Berlin 👇🏼

[Samir Abu Rumeileh @s_rumeileh]

Proud of us guys @Ahmed_Abdelhak_ @mattfos89 @luciodanna2 @QuanterixSimoa #csfsocietymeeting #biomarkers #gfap

[RikOssenkoppele @RikOssenkoppele]

Thanks @alzforum for covering our preprint about clinical progression in PET-based A+T+ cognitively normal individuals. @alexa_pichetb @OskarHansson9